JP2025512798A5 - - Google Patents

Info

Publication number
JP2025512798A5
JP2025512798A5 JP2024556449A JP2024556449A JP2025512798A5 JP 2025512798 A5 JP2025512798 A5 JP 2025512798A5 JP 2024556449 A JP2024556449 A JP 2024556449A JP 2024556449 A JP2024556449 A JP 2024556449A JP 2025512798 A5 JP2025512798 A5 JP 2025512798A5
Authority
JP
Japan
Prior art keywords
activatable
target
binding protein
anchored
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064937 external-priority patent/WO2023183923A1/en
Publication of JP2025512798A publication Critical patent/JP2025512798A/ja
Publication of JP2025512798A5 publication Critical patent/JP2025512798A5/ja
Pending legal-status Critical Current

Links

JP2024556449A 2022-03-25 2023-03-24 活性化可能な二重アンカー型マスク化分子及びその使用方法 Pending JP2025512798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323718P 2022-03-25 2022-03-25
US63/323,718 2022-03-25
PCT/US2023/064937 WO2023183923A1 (en) 2022-03-25 2023-03-24 Activatable dual-anchored masked molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025512798A JP2025512798A (ja) 2025-04-22
JP2025512798A5 true JP2025512798A5 (cg-RX-API-DMAC7.html) 2026-04-01

Family

ID=86054004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556449A Pending JP2025512798A (ja) 2022-03-25 2023-03-24 活性化可能な二重アンカー型マスク化分子及びその使用方法

Country Status (5)

Country Link
US (1) US20250333487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499685A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025512798A (cg-RX-API-DMAC7.html)
CN (1) CN119301151A (cg-RX-API-DMAC7.html)
WO (1) WO2023183923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2010108173A2 (en) 2009-03-20 2010-09-23 Reset Medical, Inc. Endotracheal tube with sensors
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US9540440B2 (en) * 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス,インコーポレイテッド 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
CN111212853A (zh) 2017-08-30 2020-05-29 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20200405890A1 (en) 2018-02-21 2020-12-31 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
BR112021008526A2 (pt) 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
WO2020236679A1 (en) 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
WO2020252358A1 (en) 2019-06-13 2020-12-17 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
US20220306745A1 (en) 2019-06-13 2022-09-29 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
EP4034171A1 (en) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
AU2021206218A1 (en) 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods

Similar Documents

Publication Publication Date Title
JP6918179B2 (ja) 高親和性sirp−アルファ試薬
Trang et al. A coiled-coil masking domain for selective activation of therapeutic antibodies
US9169470B2 (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
US10517959B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
AU2006302848B2 (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
US20230192812A1 (en) Stabilized fibronectin based scaffold molecules
JP2020534830A5 (cg-RX-API-DMAC7.html)
CN110167968B (zh) 针对her3的抗原结合蛋白
CN109641970B (zh) 穿过血脑屏障的人源化抗体及其用途
RU2012101999A (ru) РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
BR112015023589B1 (pt) Método para a produção de um conjugado de imunoligante/carga útil
JP2012511033A (ja) 多価化合物の可逆阻害用マスキングリガンド
JP2014113150A5 (cg-RX-API-DMAC7.html)
JP2012518039A5 (cg-RX-API-DMAC7.html)
CN101534865A (zh) 生物活性装配体的制备方法及其用途
JP2013505287A5 (cg-RX-API-DMAC7.html)
US20210317233A1 (en) Super Versatile Method for Imparting New Binding Specificity to Antibody
JP2014515600A5 (cg-RX-API-DMAC7.html)
CN118302445A (zh) 抗cd155抗体和抗原结合片段及其使用方法
US20250188172A1 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
Wang et al. A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting
CN118556074A (zh) 接头多肽
Maejima et al. Incorporation of a repeated polypeptide sequence in therapeutic antibodies as a universal masking procedure: A case study of T cell-engaging bispecific antibodies
Liu et al. Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands
US20190270828A1 (en) Tandem antibodies